Your shopping cart is currently empty

CXCR4 antagonist; induces mitotic catastrophe in ovarian cancer cells. Displays additive cytotoxic effects when given with taxol. Enhances the efficacy of docetaxel in a mouse model.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $1,180 | 35 days | 35 days |
| Description | CXCR4 antagonist; induces mitotic catastrophe in ovarian cancer cells. Displays additive cytotoxic effects when given with taxol. Enhances the efficacy of docetaxel in a mouse model. |
| Synonyms | CTCE 9908 |
| Molecular Weight | 1927.27 |
| Formula | C86H147N27O23 |
| Cas No. | 1030384-98-5 |
| Smiles | [C@H](CC1=CC=C(O)C=C1)(C(N[C@H](C(N[C@@H](CCCCNC([C@@H](NC([C@H](CC2=CC=C(O)C=C2)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@H](CCCCN)N)=O)=O)[C@H](C)C)=O)CO)=O)CC(C)C)=O)CO)=O)=O)CCCNC(=N)N)=O)C(N)=O)=O)CCCNC(=N)N)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@H](CCCCN)N)=O)=O)[C@@H](C)C)=O)CO)=O)CC(C)C)=O)CO)=O |
| Relative Density. | no data available |
| Sequence | Sequence 1:Lys-Gly-Val-Ser-Leu-Ser-Tyr-Arg-Lys-NH2;Sequence 1':Lys-Gly-Val-Ser-Leu-Ser-Tyr-Arg (Amide bridge:Lys9-Arg8’) |
| Sequence Short | Sequence 1:KGVSLSYRK;Sequence 1':KGVSLSYR (Amide bridge:Lys9-Arg8’) |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.